The global antiphospholipid syndrome treatment market size attained a value of USD 35.4 billion in 2021. The market is expected to grow at CAGR of 11.45% during the forecast period 2023-2031 to attain a value of USD 92.4 billion by 2030 owing to the growing cases of antiphospholipid syndrome and presence of sophisticated healthcare infrastructure.
Antiphospholipid syndrome is an immune system-associated disorder that increases the risk of blood clots. Patients suffering from antiphospholipid syndrome are at a higher risk of developing diseases like arterial thrombosis, deep vein thrombosis or blood clots in the brain.
The exact cause of the antiphospholipid syndrome is unclear, but it is projected to be an autoimmune disorder. In this disorder, the immune system secretes abnormal antibodies. These antibodies target the phospholipid proteins making the blood clot. Additional genetic, environmental, and hormonal factors are also among the plausible causes of this disorder.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The diagnosis of antiphospholipid syndrome is complex and is done with the help of blood tests and assays. There is no approved treatment region for managing antiphospholipid syndrome. Anti-coagulant medications or drugs are used to reduce the clotting symptoms and alleviate the symptoms. The most used anti-coagulators are Warfarin and Aspirin.
In case of severe symptoms or blood clots, anticoagulant injections are required. Heparin injections are widely used, which can be self-administered or given by healthcare providers.
According to the antiphospholipid syndrome treatment market research report, the market can be categorised into the following segments
Market Breakup by Indication Type
Market Breakup by Therapeutics
Market Breakup by Treatment Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growth of the market is driven by the rising prevalence of the antiphospholipid syndrome. This syndrome mainly affects the blood clotting mechanism; hence, with the increasing number of cases, there will be a rise in the demand for anti-coagulators.
The factors primarily driving the growth of the market are rapid developments in healthcare infrastructure and rising investments in the research and development sector. This will facilitate the discovery of novel therapeutic products, contributing to market expansion.
Additional factors, such as the growing ageing population and increasing awareness, contribute to the development of the market. The flexible government policies are responsible for driving the market forward during the forecast period.
North America is projected to hold a significant share of the global market due to the refined healthcare facilities and increasing patient awareness. Following North America, Europe is expected to dominate the antiphospholipid syndrome treatment market due to the wide range of therapeutic interventions and favourable regulatory guidelines.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
There is no approved treatment regimen for the management of the antiphospholipid syndrome. However, different therapeutic interventions are utilised to alleviate and control the symptoms. This syndrome mainly causes blood clotting and miscarriages.
Blood thinners or anticoagulants are considered a first-line treatment for managing blood clots. The most used anti-clotting agents are Intravenous Heparin, Oral Warfarin, and Aspirin. Patients with APS generally take oral Warfarin periodically to prevent blood clots. Aspirin is utilised to treat arterial blood clots.
Patients with recurrent miscarriages and suffering from antiphospholipid syndrome take Enoxaparin Injections, Intravenous Immunoglobin Infusions, and Corticosteroids. The combination therapy of Enoxaparin injections with low-dose Aspirin is considered a standard treatment for preventing miscarriages.
Intravenous immunoglobin infusions and corticosteroids like Prednisolone are generally incorporated to manage difficult recurrent miscarriages.
With a better understanding and advancements, the discovery of novel therapeutic agents will facilitate the expansion of the antiphospholipid syndrome treatment market.
Technological advancements and extensive research activities have been significantly contributing to the discovery of novel therapeutic interventions. APS ACTION (Anti-Phospholipid Syndrome Alliance for Clinical Trials and International Networking) is an international organisation developed to conduct large-scale clinical trials for antiphospholipid antibody patients.
APS ACTION has collaborated with investigators for interventional clinical studies. These studies will help better understand the underlying mechanisms and facilitate the conduction of large-scale clinical trials to diagnose and manage antiphospholipid syndrome.
A novel drug, Defibrotide, has been found effective in treating blood clots. This drug is anticipated to treat blood clotting in antiphospholipid syndrome patients. This drug is under exploratory trials to understand its detailed therapeutic mechanism.
BeLimumab Antiphospholipid Syndrome Trial (BLAST) is an undergoing clinical study to test the drug belimumab's safety and efficacy. This drug is generally tested for patients resistant to warfarin or heparin.
Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for novel drug therapies. Careful planning and research are done to overcome all the hurdles and hindrances and for the vast development. Several ongoing clinical trials are emerging as a driving factor for market growth and development.
The report gives an in-depth analysis of the key players involved in the antiphospholipid syndrome treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Indication Type||
|Breakup by Treatment Type||
|Breakup by Treatment Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Antiphospholipid Syndrome Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Antiphospholipid Syndrome Treatment Market
6.1 Global Antiphospholipid Syndrome Treatment Market Overview
6.2 Global Antiphospholipid Syndrome Treatment Market Analysis
6.2.1 Market Overview
188.8.131.52 Global Antiphospholipid Syndrome Treatment Market Historical Value (2016-2022)
184.108.40.206 Global Antiphospholipid Syndrome Treatment Market Forecast Value (2023-2031)
6.3 Global Antiphospholipid Syndrome Treatment Market by Indication Type
6.3.1 Market Overview
220.127.116.11 Primary Antiphospholipid Syndrome
18.104.22.168 Secondary Antiphospholipid Syndrome
22.214.171.124 Catastrophic Antiphospholipid Syndrome
6.4 Global Antiphospholipid Syndrome Treatment Market by Treatment Type
6.4.1 Market Overview
126.96.36.199 Preventative (Prophylaxis) Therapy
6.5 Global Antiphospholipid Syndrome Treatment Market by Treatment Channel
6.5.1 Market Overview
6.6 Global Antiphospholipid Syndrome Treatment Market by Region
6.6.1 Market Overview
188.8.131.52 North America
184.108.40.206 Asia Pacific
220.127.116.11 Middle East and Africa
18.104.22.168 Latin America
7 North America Antiphospholipid Syndrome Treatment Market
7.1 Market Share by Country
7.2 United States of America
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
7.3.1 Historical Trend (2016-2022)
7.3.2 Forecast Trend (2023-2031)
8 Europe Antiphospholipid Syndrome Treatment Market
8.1 Market Share by Country
8.2 United Kingdom
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
8.5.1 Historical Trend (2016-2022)
8.5.2 Forecast Trend (2023-2031)
9 Asia Pacific Antiphospholipid Syndrome Treatment Market
9.1 Market Share by Country
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
9.6.1 Historical Trend (2016-2022)
9.6.2 Forecast Trend (2023-2031)
10 Latin America Antiphospholipid Syndrome Treatment Market
10.1 Market Share by Country
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
11 Middle East and Africa Antiphospholipid Syndrome Treatment Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 United Arab Emirates
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 South Africa
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
12 Global Antiphospholipid Syndrome Treatment Market Dynamics
12.1 Market Drivers and Constraints
12.2 SWOT Analysis
12.3 Porter’s Five Forces Model
12.4 Key Demand Indicators
12.5 Key Price Indicators
12.6 Industry Events, Initiatives, and Trends
12.7 Value Chain Analysis
13 Supplier Landscape
13.1 Cipla Limited
13.1.1 Company Overview
13.1.2 Product Portfolio
13.1.3 Demographic Reach and Achievements
13.1.4 Mergers and Acquisitions
13.2 Pfizer Inc.
13.2.1 Company Overview
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.3 Zydus Lifesciences Limited
13.3.1 Company Overview
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.4 Bristol-Myers Squibb Company
13.4.1 Company Overview
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.5 Sawai Pharmaceutical Co., Ltd.
13.5.1 Company Overview
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.6 Amneal Pharmaceuticals
13.6.1 Company Overview
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.7 Novartis AG
13.7.1 Company Overview
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.8 Fresenius SE & Co. KGaA
13.8.1 Company Overview
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.9 Hikma Pharmaceutics plc
13.9.1 Company Overview
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.10 Teva Pharmaceutical Industries Ltd.
13.10.1 Company Overview
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.11 Mylan N.V.
13.11.1 Company Overview
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
14 Global Antiphospholipid Syndrome Treatment Market- Drug Distribution Model (Additional Insight)
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Payment Methods (Additional Insight)
15.1 Government Funded
15.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market size attained a value of USD 35.4 billion in 2021.
The market is expected to grow at CAGR of 11.45% during the forecast period 2023-2031 to attain a value of USD 92.4 billion by 2030.
The increasing prevalence of antiphospholipid syndrome and rapid developments in the research and development sector are primarily driving the market growth.
Based on the type, the market can be segmented into primary antiphospholipid syndrome, secondary antiphospholipid syndrome, and catastrophic antiphospholipid syndrome.
Based on the treatment method, the market is divided into medications, preventative (prophylaxis) therapy and others.
Based on the treatment method, the market can be categorised into public and private.
On a regional level, the market has been categorised into North America, Latin America, Europe, Asia Pacific, the Middle East and Africa. North America is anticipated to account for the largest share of the market.
The key companies involved in the market are Cipla Limited, Pfizer Inc., Zydus Lifesciences Limited, Bristol-Myers Squibb Company, Sawai Pharmaceutical Co., Ltd., Amneal Pharmaceuticals, Novartis AG, Fresenius SE & Co. KGaA, Hikma Pharmaceutics plc, Teva Pharmaceutical Industries Ltd., and Mylan N.V., among others.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.